NDAORALCAPSULEPriority Review
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
7
Data completeness
6/8 — Strong
Priority Review
VONJO (pacritinib) by Akesobio is tyrosine kinase inhibitors [moa]. Approved for primary myelofibrosis, post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VONJO (pacritinib) is an oral tyrosine kinase inhibitor approved in February 2022 for the treatment of myelofibrosis. It works by inhibiting JAK2, IRAK1, and TYK2 signaling pathways, which are dysregulated in myeloproliferative neoplasms. The product is marketed by Akesobio and represents a targeted therapeutic option within the kinase inhibitor class for patients with myelofibrosis.
$0.1BPart D
3.9 years to LOEMechanism of Action
Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Worked on VONJO at Akesobio? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.